The immune systems of cancer patients are highly disrupted, with those who have a higher number of immune cells in their blood having a better survival rate, finds a new study that uses a pioneering ...

All nine patients treated with a personalized cancer vaccine following removal of their tumors remained cancer-free at a median data cut-off of 34.7 months.

Colorectal cancer (CRC) is one of the most prevalent types of cancer and has a high mortality rate globally. Oral ...

Luminescent gold nanoparticles (L-AuNPs) represent a novel class of luminescent nanomaterials that have attracted ...

Merck (MRK) stock in focus as anti-cancer agent Welireg is approved in the EU for kidney tumor conditions, VHL disease and ...

The FDA granted fast track status to IBI363 for the treatment of patients with advanced squamous lung cancer after prior ...

Integrative cancer care merges conventional treatments like chemotherapy and surgery with research-based traditional medicine. While traditional medicine can weaken cancer cells and protect normal ...

Casdatifan targets a transcription factor that binds with other proteins to switch off the body’s anti-inflammatory mechanisms, empowering genes that promote tumor growth in clear cell renal cell ...

Aston University is collaborating in research to develop an injectable paste which could treat bone cancer.

Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated cancers, especially mCRC. See why I rate CRDF stock as a ...

The immune systems of cancer patients are highly disrupted, with those who have a higher number of immune cells in their blood having a better survival rate, finds a new study that uses a pioneering ...

NT219, a novel agent designed to overcome tumor resistance to drug therapy, will be evaluated in combination with the standard-of-care head and ...